08.02.2019 • News

Evonik’s C4Buy Platform Moves toward Full Run

Evonik’s C4Buy Platform Moves toward Full Run (c) Evonik
Evonik’s C4Buy Platform Moves toward Full Run (c) Evonik

A new B2B trading platform operated by specialty chemicals producer Evonik, which opened trials late last year under the name C4Buy, is gearing up for full-time operation, the Essen, Germany-based group said.

Customers for products manufactured by Evonik’s Performance Intermediates (PI) business segment soon will have round the clock access to product offers, purchase orders and invoices and also submit bids for spot quantities of specific PI products via C4Buy.

Products now for sale on the platform are primarily C4-based materials for the rubber, plastics and specialty chemicals market, including methyl tert-butyl ether (MTBE) an anti-knocking agent for gasoline production, in addition to n-butane and 1,3-butadiene.

As a key part of the process, Evonik Performance Materials is working with customers to develop digital solutions for transforming conceptual ideas into workable solutions.

The complementary services “keep gaining relevance in addition to product offerings,” Evonik said.  Along with getting an overview of their business relationship, customers will have online access to contract documents and can participate in an interactive planning process.

Since the first tests of the system with pilot customers, larger numbers of customers have been accessing the C4Buy platform, and a formal roll-out is planned for some time this year.

The group plans to begin offering additional products over the course of this year, and this, it said,  will go hand in hand with further enhancement of the platform.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read